1-3 of 3
Robert Orlowski, MD
Close
Sort by
Journal Articles

Integrated Immunological Analysis of the Bone Marrow Tumor Microenvironment in Myeloproliferative Neoplasms to Determine Potential Efficacy of Immune Checkpoint Blockade

Robert Orlowski, MD, Alexander Huang, Mercy Gohil, James Mangan, MD PhD, Marissa Vignali, PhD, Ryan O Emerson, PhD, Harlan Robins, PhD, Erik Yusko, PhD, Martha S Jordan, PhD, Martin Carroll, MD, D. Gary Gilliland, MD PhD, Elizabeth O Hexner, MD
Journal: Blood
Blood (2015) 126 (23): 2766.
https://doi.org/10.1182/blood.V126.23.2766.2766
Published: 2015
Journal Articles

Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM)

Ravi Vij, MD, Michael Wang, MD, Robert Orlowski, MD, PhD, A. Keith Stewart, MBChB, Sundar Jagannath, MD, Vishal Kukreti, MD, FRCPC, Jessica Taylor, BA, Diana Fuhrman, BSN, Scott Cruickshank, MS, Richard Schwartz, MD, Lori Kunkel, MD, David Siegel, MD, PhD, The Multiple Myeloma Research Consortium (MMRC)
Journal: Blood
Blood (2008) 112 (11): 865.
https://doi.org/10.1182/blood.V112.11.865.865
Published: 2008
Journal Articles

Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib ± Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma.

Robert Orlowski, MD, PhD, Heather Sutherland, MD, PhD, Joan Bladé, MD, Jesús San Miguel, MD, Roman Hájek, MD, PhD, Arnon Nagler, MD, MSc, Pieter Sonneveld, MD, PhD, Andrew Spencer, DM, Tadeusz Robak, MD, PhD, Suneel Mundle, PhD, Donghan Luo, PhD, Sen Hong Zhuang, MD, PhD, Jean-Luc Harousseau, MD
Journal: Blood
Blood (2007) 110 (11): 2735.
https://doi.org/10.1182/blood.V110.11.2735.2735
Published: 2007